Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Update

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 11,400 shares, an increase of 2,750.0% from the March 31st total of 400 shares. Based on an average daily trading volume, of 206,900 shares, the short-interest ratio is presently 0.1 days.

Oncotelic Therapeutics Stock Performance

Shares of OTLC opened at $0.04 on Friday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.02 and a current ratio of 0.02. Oncotelic Therapeutics has a 1 year low of $0.01 and a 1 year high of $0.05. The stock’s 50-day moving average price is $0.04 and its two-hundred day moving average price is $0.04.

About Oncotelic Therapeutics

Oncotelic Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.